EFFECT ·Filed May 26, 2026
SC

SCLXW

Scilex Holding Co
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC9999999995-26-001743
IPO/offering going effective
Actionable Insight ▼ Bearish

The shelf being effective means Scilex can sell shares at any time. For SCLXW warrant holders, any common stock issuance below the warrant exercise price would destroy warrant value. Monitor for a prospectus supplement (424B5) indicating an actual takedown — that would be the execution event. Given the tiny market cap, even a small issuance would be highly dilutive.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
SCLXW ▲ 0.00% at T+20d
SHORT call ✗ call lost 0.00% · α vs SPY -2.06% · entry $0.1360 → $0.1360
Next anchor: T+60d due 6w ago
Latest observation: T+26 -2.39% FF3 residual α
Entry anchored
May 26, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.01%
$0.1360
settled 4mo ago
T+5d
0.00%
call 0.00% · α +1.21%
$0.1360
settled 4mo ago
T+20d
0.00%
call 0.00% · α -2.06%
$0.1360
settled 3mo ago
T+60d
—
call — · α —
—
due 6w ago

Price Chart

Loading chart...

Executive Summary

Scilex Holding Co's Form S-3 shelf registration (File No. 333-295109) was declared effective by the SEC on May 22, 2026. This allows the company to sell up to $500 million in securities at its discretion, creating a significant dilution overhang for the warrant holders (SCLXW). The company's market cap is only ~$1M, meaning any takedown from this shelf would be massively dilutive relative to current equity value.

Key Facts

  • Shelf registration (S-3) declared effective on 2026-05-22 under File No. 333-295109
  • Offering size is up to $500 million in securities (common stock, preferred, debt, warrants, rights, units)
  • Company market cap is approximately $1 million — the shelf size is ~500x current market cap
  • This is a follow-on shelf effectiveness, not an IPO; the company has been public since a prior de-SPAC merger
  • Cross-filing context: S-1 filed 2025-12-16 (161 days ago) and S-3 filed 2026-04-16 (40 days ago) both now effective

Financial Impact

Up to $500 million in potential dilution against a ~$1M market cap — extreme dilution risk

dilutionshare countequity value

Risk Factors

  • Immediate dilution risk if the company executes any takedown from the shelf
  • Warrant overhang: SCLXW holders face potential exercise dilution if common stock is issued below warrant strike
  • Company may be forced to issue equity to fund operations, given the small market cap and biotech cash-burn profile

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001743
Document: 9999999995-26-001743-index.html9999999995-26-001743
Document: 9999999995-26-001743.txt9999999995-26-001743
5 reports for SCLXW
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SCLXW — sortable, filterable
TypeNow
Jun 2, 2026
17w ago
S-3
BEARISH ★ 6/10
$0.1360 $0.1800▼ −32.35%▼ −33.35%—
May 26, 2026
18w ago
EFFECT
BEARISH ★ 6/10
$0.1360 $0.1360· 0.00%▼ −2.06%—
May 5, 2026
21w ago
8-K
BULLISH ★ 8/10
$0.1360 $0.1360· 0.00%▼ −4.95%—
Apr 28, 2026
22w ago
8-K
MIXED ★ 6/10
$0.1360 $0.1360· 0.00%▼ −6.05%—
Apr 16, 2026
24w ago
S-3
NEUTRAL ★ 4/10
$0.1360 $0.1360· 0.00%▼ −5.37%—
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (54h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access